After busy Thanksgiving get-togethers and frantic Black Friday, Small-Business Saturday, and Cyber Monday shopping, many people take a moment to reflect and give back to a cause that captures their passion. Dubbed Giving Tuesday, it’s a day dedicated to philanthropy and fundraising. For the first time ever, the Oncology Nursing Foundation issued a Giving Tuesday challenge to ONS chapters—a friendly competition to see which group could get the highest percentage of its membership to donate to the continued growth and excellence of oncology nursing.

Already the third leading cause of cancer deaths worldwide, hepatocellular carcinoma (HCC) is a continually growing burden as the incidence of obesity, type II diabetes, and hypertension also increase, which may lead to cirrhosis and nonalcoholic fatty liver disease. Its incidence is highest in Asia and Africa, where the prevalence of hepatitis B and hepatitis C may result in chronic liver disease and subsequently HCC. 

Incidence of melanoma in the head and neck areas increased 51.1% from 1995 to 2014, according to findings from a study published in JAMA Otolaryngology.

Clostridium difficile infection is a dangerous and sometimes deadly adverse event in immunocompromised patients with cancer. Although transmission risk is high in the hospital setting, even with isolation precautions, oncology providers can use a variety of prevention techniques to reduce the chance for infection in their patients.

Lymphedema is one of the most common treatment side effects in patients with breast cancer. Estimates suggest that approximately 40% of all breast cancer survivors are at risk to develop lymphedema at some point in their lives. But as far back as 1998 and even before, some healthcare experts were predicting that lymphedema would be eliminated as a side effect from breast cancer treatment. Twenty-one years later, it’s still prevalent among breast cancer survivors, requiring careful management recommendations from oncology nurses to help patients live with this chronic issue.

Connection, creativity, and change were just some of the components of the ONS Board of Directors’ third-quarter face-to-face meeting held October 31–November 3, 2019. In addition to their regular agenda, the ONS Board conducted enterprise-wide joint and individual meetings with the Oncology Nursing Certification Corporation and Oncology Nursing Foundation boards.

Addressing the rising costs of prescription medications is a key priority for the Trump administration. As patients struggle with the financial burden of high drug prices, the U.S. Food and Drug Administration is reviewing options to import medications from Canada at a lower cost to consumers. However, the plan has major hurdles that FDA must address before it can become a reality.

Technology is great when you get it. But when you don’t, it can be a real burden, and an extra burden is the last thing a patient with cancer needs. Fortunately, at the Moffitt Cancer Center in Tampa, FL, we’ve found a program that not only helps our nurses and our patients with technology, but it also brings our older patient population together with the positive energy of younger members. 

On December 3, 2019, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq®) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.